Announced details
Gene therapy, cell therapy and the treatment of various diseases
Alexion, AstraZeneca Rare Disease is one of the Company’s partners. The Company’s relationship with ASGCT is that of a conference presenter.
ASGCT is a leading professional organization in gene and cell therapy. The location, representative, business activities and other information concerning Alexion, AstraZeneca Rare Disease are not disclosed.
Boston, Massachusetts (venue for the ASGCT 29th Annual Meeting)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
| Item | Details |
|---|---|
| Names of Products / Services Covered | JUST-AAV |
| Counterparty | Alexion, AstraZeneca Rare Disease, American Society of Gene and Cell Therapy (ASGCT) |
| Counterparty overview | ASGCT is a leading professional organization in gene and cell therapy. The location, representative, business activities and other information concerning Alexion, AstraZeneca Rare Disease are not disclosed. |
| Relationship with the Company | Alexion, AstraZeneca Rare Disease is one of the Company’s partners. The Company’s relationship with ASGCT is that of a conference presenter. |
| Launch date | 11 May 2026 (scheduled start date of the conference) |
| Applicable area | Gene therapy, cell therapy and the treatment of various diseases |
| Location | Boston, Massachusetts (venue for the ASGCT 29th Annual Meeting) |
| Source | American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To present preclinical research data on platform technologies, including JUST-AAV, at the ASGCT 29th Annual Meeting.